more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Healthcare Co. Exceeds Expectations in Performance

Research Report
  ()
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.

Money Manager: The Year of Small Caps?

  ()
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps.

Big Pharma's Looming Patents May Benefit One Biotech

  ()
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024.

Biotech Co.'s Sales Could Grow To US$310 Million in 2028

Research Report
  ()
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.

2024: Chen Leads With Biotech After Picking 2023's Top Stock

  ()
Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year.

Market Correction and One Cash Rich Biotech

Contributed Opinion
  ()
In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value.

Boston Biotech Could Have Blockbuster Sales

Research Report
  ()
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.

Pharma Co. Gets First US Patent for Repurposed Drug

  ()
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast.

California-Based Pharma Co.'s Progress Offers Upside

Research Report
  ()
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.

Co.'s Breast Cancer Therapy Shows Encouraging Activity

Research Report
  ()
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.

Biotech Secures Additional Funding, Extending Cash Runway

Research Report
  ()
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.

Biotech Bolsters ADC Pipeline Through Atreca Asset Buy

Research Report
  ()
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.

US Biotech's Anti-Fungal Wins European Approvals

Research Report
  ()
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.

Biotech Co. Reports Encouraging ALS Data but FDA Wants More

Research Report
  ()
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.

Pharma Co. May Have Accelerated FDA Approval in 2024

Research Report
  ()
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co.

Bioscience Co. Expands Collaboration

Research Report
  ()
This bioscience company's price target implies 680% upside, according to a Roth MKM report.

Promising Biotech Selling Way Under Cash Value

Contributed Opinion
  ()
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater.

Showing Results: 26 to 42 of 42 Prev